Gastrointestinal issues such as nausea, vomiting, constipation and diarrhoea are common, with more serious complications including gallbladder inflammation and pancreatitis reported in a minority of patients
The results showed that there was a reduced relative and absolute risk of MACE with semaglutide vs comparators across the spectrum of baseline CV risk scores
Although the evidence is limited, preliminary findings suggest that people using semaglutide for diabetes or obesity management sometimes report improvements in pain levels, including musculoskeletal discomfort
Bryk J, Mellon SH, Epel ES, Blackburn E, Lin J, Lustig RH, Havel PJ, Reus VI, Burke H, Rosser R, Coetzee J, Mahan L, Coy M, Hamilton S, Nelson JC, Wolkowitz OM: Serum leptin concentrations and telomere length in MDD and in controls
Wash and chop vegetables in advance store in containers for quick assembly